【摘要】 目的了解产超广谱β-内酰胺酶(ESBLs)大肠埃希菌的检出及其耐药变化,为临床合理使用抗菌药物提供参考。方法收集某院2006年1—12月间临床标本分离的大肠埃希菌,对其产ESBLs株及耐药情况与2002年进行比较。结果2006年分离的大肠埃希菌中产ESBLs株占65.54%(175/267),与2002年的47.92%(46/96)比较,显著增加(χ2=9.21,P<0.05)。产ESBLs大肠埃希菌对氨曲南的敏感率2006年为24.00%,较2002年的52.17%显著下降(χ2=13.80,P<0.05);对其他抗菌药物的敏感率差异无统计学意义,亚胺培南仍对产ESBLs大肠埃希菌有良好的抗菌活性。结论产ESBLs大肠埃希菌的检出有增加趋势,且耐药率高,应引起临床重视。更多还原

【Abstract】 ObjectiveTo investigate the detection and change in drug-resistance of extended-spectrum β-lactamase (ESBLs)-producing Escherichia coli,so as to provide reference for the rational use of antimicrobial agents in clinic.MethodsEscherichia coli isolated from clinic in a hospital between January~December,2006 were collected,the detection of ESBLs and drug-resistance were compared with those of 2002. ResultsThe rate of ESBLs-producing Escherichia coli isolated in 2006 was 65.54% (175/267),which increased obviously compared with 47.92% (46/96) isolated in 2002 (χ2=9.21,P<0.05). The susceptibility rate of ESBLs-producing Escherichia coli to imipenem in 2006 was 24.00%,which decreased obviously compared with 52.17% in 2002 (χ2=13.80,P<0.05); The susceptibility rates to the other antimicrobial agents had no statistic significance,imipenem still had ideal activity against ESBLs-producing Escherichia coli. ConclusionThere is increasing tendency in the detection of ESBLs-producing Escherichia coli,and drug-resistance is high,which should be paid attention.更多还原